|
Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses Koup RA, et al.
Journal of Immunology
2003, 171: 4320-4328
Link Optimal Ag targeting and activation of APCs, especially dendritic cells (DCs), are important in vaccine development. In this study, they report the effects of different Toll-like receptor (TLR)-binding compounds to enhance immune responses induced by human APCs, including CD123+ plasmacytoid DCs (PDCs), CD11c+ myeloid DCs (MDCs), monocytes, and B cells. Together, the data show that targeting specific DC subsets using TLR ligands can enhance their ability to activate virus-specific T cells, providing information for the rational design of TLR ligands as adjuvants for vaccines or immune modulating therapy.
—Posted: November 11, 2003
More journal headlines: This month | Last month | Search archive
|
